Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Proof of Concept Study of Abatacept (Orencia) in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis

NCT04261023 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.

NCT NCT04261023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04261023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Proof of Concept Study of Abatacept (Orencia) in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis
Lead sponsor
University of Leeds
Phase
Phase 2
Overall status
Terminated
Start date
February 24, 2020
Completion date
March 15, 2021
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory arthritis